New radioactive tracer could spot hidden cancers
NCT ID NCT05940298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed phase 1 trial tested a radioactive imaging agent called [99mTc]Tc-DB8 in 10 people with prostate or breast cancer. The goal was to see how the agent spreads in the body and whether it can help detect tumors using SPECT scans. Researchers also checked for safety and compared the images to standard scans like CT or MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[99mTc]Tc-DB8 (a radioactive imaging agent)
What this could lead to
If successful, this could lead to a new way to detect prostate and breast cancer tumors using SPECT imaging, potentially improving diagnosis.
What could go wrong
This is a very early, small study (10 people) that only looks at imaging, not treatment. The agent may not clearly show tumors or could have safety issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
TomskNRMC
Tomsk, Russia